Lv6
1690 积分 2022-11-03 加入
吡咯替尼联合抗血管生成药物治疗HER2突变的晚期非小细胞肺癌
5小时前
待确认
Antitumor activity of daphnodorins from Daphne genkwa roots
5小时前
已完结
芫花中Meroterpenoids在A549细胞中通过抑制PI3K/Akt/mTOR信号通路表现良好抗肿瘤活性的研究新进展
5小时前
求助中
EGFR TKI combination with immunotherapy in non-small cell lung cancer. 🗍 Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K
2天前
已完结
Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer
2天前
已完结
Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer
2天前
已完结
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
2天前
已完结
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer
2天前
已完结
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
2天前
已完结
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2天前
已完结
皖公网安备34019202002308
